Yacine Saidi

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial.

Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 16, 2025

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 16, 2025

Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents.

Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents.

Journal: AIDS (London, England)

Published: January 27, 2025

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.

Journal: Antimicrobial agents and chemotherapy

Published: December 13, 2023

Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.

Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.

Journal: The lancet. HIV

Published: November 07, 2023

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.

Journal: EClinicalMedicine

Published: March 09, 2023

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.

Journal: The Journal of antimicrobial chemotherapy

Published: October 15, 2022

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.

Journal: The New England journal of medicine

Published: December 29, 2021

Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.

Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.

Journal: HIV medicine

Published: November 24, 2019

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.

Journal: PloS one

Published: October 30, 2017

Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: December 01, 2016

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: September 01, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026